- Conditions
- COPD
- Interventions
- Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo
- Drug
- Lead sponsor
- Gary L. Pierce
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 1,670
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Caregiver Stress Syndrome, Anxiety
- Interventions
- Mindfulness Coach, Active Comparator
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Livingston, New Jersey • Monroe, New Jersey • New Brunswick, New Jersey
- Conditions
- Bioequivalence of Vitamin D in Healthy Adults
- Interventions
- vitamin D3
- Dietary Supplement
- Lead sponsor
- Church & Dwight Company, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Depressive Disorder and Anxiety Disorders
- Interventions
- single dose
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Psoriatic Arthritis
- Interventions
- Zasocitinib, Active Comparator, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,088 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- TT223 with Metformin and/or TZD, Placebo with Metformin and/or TZD
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 20
- States / cities
- Artesia, California • Los Angeles, California • Santa Ana, California + 17 more
- Conditions
- Tonsillectomy
- Interventions
- Intravenous ibuprofen, Normal Saline
- Drug · Other
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Newark, New Jersey • Charlotte, North Carolina + 3 more
- Conditions
- Posttraumatic Headache, Posttraumatic Stress Disorder
- Interventions
- Group A active comparator, Group B active comparator, Group C Experimental, Group D Placebo Comparator
- Procedure · Drug · Combination Product + 1 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Fort Bragg, North Carolina
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg, BNT162b4 15 mcg, BNT162b4 30 mcg, BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Tempe, Arizona • Newport Beach, California • San Diego, California + 13 more
- Conditions
- Mental Health
- Interventions
- immi, Control
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Rib Fracture, Rib Fracture Multiple
- Interventions
- Cryoneurolysis, Local anesthetic peripheral nerve block, Sham Cryoneurolysis, Sham peripheral nerve block
- Device · Procedure
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 5
- States / cities
- La Jolla, California • Bethesda, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Attention Deficit/Hyperactivity Disorder(ADHD)
- Interventions
- Vyvanse, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- HU6, Placebo
- Drug
- Lead sponsor
- Rivus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Torrance, California • Hialeah, Florida + 11 more
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501, Sham
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Colorado Springs, Colorado • Atlanta, Georgia + 18 more
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Drug
- Lead sponsor
- Envisia Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
- Conditions
- Contraception
- Interventions
- SpeakOut, PartyWise
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 15 Years to 20 Years · Female only
- Enrollment
- 1,099 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Inherited Erythromelalgia
- Interventions
- PF-05089771, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes (T1D)
- Interventions
- SAB-142, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more
- Conditions
- Kidney Failures, Acute
- Interventions
- Intra-Renal Fenoldopam, Furosemide
- Drug
- Lead sponsor
- Southeast Renal Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chattanooga, Tennessee
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more
- Conditions
- Genital Warts, Perianal Warts
- Interventions
- NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%
- Drug
- Lead sponsor
- Novan, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- Fountain Valley, California • Lomita, California • San Diego, California + 11 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin Lispro low mixture
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 30 Years to 79 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 13
- States / cities
- La Jolla, California • Walnut Creek, California • New Britain, Connecticut + 10 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Aflibercept, Faricimab, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more